COMBINING IAP ANTAGONISTS WITH CAR T CELL THERAPY TO TREAT GLIOBLASTOMA: THE IAP ANTAGONIST BIRINAPANT ENHANCES CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY FOR GLIOBLASTOMA BY OVERCOMING ANTIGEN HETEROGENEITY
Degree type
Graduate group
Discipline
Medical Sciences
Biology
Subject
Birinapant
CAR T Cell
Glioblastoma
IAP Antagonist
Funder
Grant number
License
Copyright date
Distributor
Related resources
Author
Contributor
Abstract
Antigen heterogeneity that results in tumor antigenic escape is one of the major obstacles to successful chimeric antigen receptor (CAR) T cell therapies in solid tumors including glioblastoma multiforme (GBM). To address this issue and improve the efficacy of CAR T cell therapy for GBM, we developed an approach that combines CAR T cells with inhibitor of apoptosis protein (IAP) antagonists, a new class of small molecules that mediate the degradation of IAPs, to treat GBM. Here, we demonstrated that the IAP antagonist birinapant could sensitize GBM cell lines and patient-derived primary GBM organoids to apoptosis induced by CAR T cell-derived cytokines, such as tumor necrosis factor. Therefore, birinapant could enhance CAR T cell-mediated bystander death of antigen-negative GBM cells, thus preventing tumor antigenic escape in antigen-heterogeneous tumor models in vitro and in vivo. In addition, birinapant could promote the activation of NF-κB signaling pathways in antigen-stimulated CAR T cells, and with a birinapant-resistant tumor model, we showed that birinapant had no deleterious effect on CAR T cell functions in vitro and in vivo. Overall, we demonstrated the potential of combining the IAP antagonist birinapant with CAR T cells as a promising approach to overcoming tumor antigen heterogeneity and enhancing CAR T cell therapy for GBM.